Can Nitazoxanide and/or other anti‐viral medications be a solution to long COVID? Case report with a brief literature review
0301 basic medicine
herpesviruses
Medicine (General)
R
Case Report
latent virus reactivation
03 medical and health sciences
R5-920
COVID‐19
anti‐viral medication
Medicine
acyclovir
long COVID
DOI:
10.1002/ccr3.8162
Publication Date:
2023-11-17T08:57:06Z
AUTHORS (1)
ABSTRACT
Key Clinical MessageFindings here imply lingering of virus, SARS‐CoV‐2, in the body for months. Thus, Nitazoxanide and/or other anti‐viral medications might be potential options to combat long COVID. This could transform treatment for long COVID patients globally.AbstractLong COVID or post‐acute sequelae of COVID‐19 (PASC) continues to affect many people even after a relatively mild acute illness. Underlying causes of PASC are poorly understood. There is no particular treatment or management program developed yet. Thus, the possibility of well‐known, safe anti‐viral medications use against PASC is proposed here.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (84)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....